As medical devices grow increasingly complex, the need for enhanced safety oversight has become more pressing. The discipline of materiovigilance involves continuously monitoring, assessing, and reporting safety concerns related to medical devices on the market, enabling organizations and regulatory agencies to identify potential issues with device malfunctions, usability, or software. In contrast to pharmacovigilance, which focuses on treatment safety, materiovigilance examines how users interact with devices in real-world settings. With the convergence of connected devices, diagnostics, and digital tools with therapies, materiovigilance will play a central role in post-market safety oversight, particularly as Dr. Padmalakshmi Jnaneshwar notes, it will become essential for ensuring patient safety.
Building New Capabilities
Companies face hurdles as they adapt to broader safety responsibilities, particularly when shifting from drug monitoring to device oversight. While pharmaceutical firms excel at tracking medication risks, medical device safety demands distinct procedures, specialized knowledge, and different types of evidence. What seems like a simple device malfunction might stem from flaws in design, software bugs, user errors, or improper usage conditions. Without structured frameworks, teams risk slow reporting, incomplete analyses, and regulatory violations.
Effective governance is another cornerstone of successful materiovigilance. It ensures collaboration between safety teams while clarifying responsibilities across departments like regulatory affairs, quality control, clinical operations, manufacturing, and IT. Without clear governance, confusion over roles can lead to missed deadlines and lost critical information. Strong governance frameworks shift teams from handling cases reactively to adopting a proactive, lifecycle-wide approach, complete with defined accountability (RACI) and escalation protocols.
Applying AI to Materiovigilance
Artificial intelligence offers significant benefits for the pharmaceutical sector. To realize this value, teams must apply it to specific operational issues. AI can detect duplicate records or information, route complaints to the correct groups, and uncover trends that humans might miss. It also aids in classifying information according to established rules.
Unifying Data Sources
The volume of safety alerts for medical devices has surged, coming from sources like customer service lines, production records, digital health platforms, distributors, maintenance logs, and healthcare providers. Because these signals are isolated, analyzing them becomes far more difficult. Scattered data prevents meaningful trend analysis since teams lack complete datasets to work with.
Related Post: Fragmented Data Masks Early Medical Device Risks
Creating a unified data strategy does not require every system to be identical. What materiovigilance teams need to catch and analyze these signals is a set of common definitions, consistent coding practices and clear pathways for information to move between functions. With these baselines established, teams should have a clearer understanding of where relevant data originates, how it is classified and who can access it when an investigation begins. As these filters are fine-tuned, organizations can become better and faster at detecting and responding to emerging issues.
While materiovigilance teams create new processes independent of their pharmacovigilance counterparts, some level of collaboration is still expected. Combination products, such as insulin delivery systems, often create safety questions that bridge the two operating models. Patients may submit complaints about adverse events related to their medication or comment on the quality of the device. In this situation, both materiovigilance and pharmacovigilance teams can leverage an integrated workflow that helps them process events quickly and mitigate the risk that information is siloed by one team or the other.
Ensuring Compliance and Scalability
Companies should focus on technology that meets compliance standards, supports audits, and scales globally. The most useful systems aren’t always the most cutting-edge; they should streamline workflows, ensure consistent classifications, and maintain traceability across regions. AI and automation can strengthen materiovigilance, but only if built on a controlled structure with audit trails, role-based decisions, version control, and transparent outputs.
The Path Forward
As medical treatments grow more interconnected with digital tools, materiovigilance will play an even larger role. Firms that now invest in unified data systems, device-specific expertise, and practical automation will respond to issues more quickly. Without these advancements, they’ll remain slow to react and fail to meet patient and regulatory demands.
Materiovigilance is more than case processing; it helps organizations build a safety function that uses real-world product experiences to continuously learn. Materiovigilance will mature when organizations bridge the gap between pharmacovigilance and device vigilance without losing specialized expertise. Strong standardization practices and disciplined technology adoption will also support that progress.
